Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines
Year: 2011
Type: article
Abstract: Background Heart failure (HF) remains a therapeutic challenge with high morbidity and mortality and frequent hospitalizations. Activators of guanylyl cyclase (GC) A and/or GCB such as naturally occurring or designer natriuretic peptides (NPs) are promising candidates for chronic drug therapy; however, parenteral administration is required. Pumps or subcutaneous administration similar to those used for insulin therapy are an attractive means of enabling chronic peptide delivery. Cenderitide (also known as CD-NP) is a Mayo designed chimeric NP consisting of C-type NP with the C-terminus of Dendroaspis NP currently in clinical development for the treatment of HF. Cenderitide is a dual agonist at both GC-A and GC-B and is relatively resistant to enzymatic degradation. This study was designed to assess the bioavailability of cenderitide when given as a subcutaneous (SQ) bolus as compared to an intravenous (IV) bolus. Hypothesis We hypothesized that given cenderitide’s relative resistance to enzymatic degradation it would have good SQ bioavailability as compared to IV administration. Methods
Source: BMC Pharmacology
Institution: Mayo Clinic
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W1993552206